HC Wainwright Estimates Cytokinetics Q3 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Cytokinetics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will earn ($2.03) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ FY2026 earnings at ($7.12) EPS, FY2027 earnings at ($5.12) EPS and FY2028 earnings at ($1.67) EPS.

CYTK has been the topic of several other reports. Bank of America restated a “neutral” rating on shares of Cytokinetics in a report on Wednesday. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Barclays began coverage on Cytokinetics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 target price for the company. Truist Financial lifted their price target on Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. Finally, The Goldman Sachs Group set a $95.00 price objective on Cytokinetics and gave the stock a “buy” rating in a research report on Thursday, December 18th. Seventeen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cytokinetics currently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

Cytokinetics Price Performance

NASDAQ CYTK opened at $62.22 on Friday. The company has a fifty day moving average price of $64.20 and a 200-day moving average price of $58.58. The firm has a market cap of $7.61 billion, a price-to-earnings ratio of -9.53 and a beta of 0.54. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $70.98.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The company had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the firm earned ($1.26) earnings per share. The company’s revenue was up 4.9% compared to the same quarter last year.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $61.93, for a total transaction of $928,950.00. Following the sale, the executive vice president directly owned 50,440 shares of the company’s stock, valued at $3,123,749.20. This represents a 22.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the completion of the transaction, the executive vice president owned 138,552 shares of the company’s stock, valued at $8,484,924.48. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 151,385 shares of company stock worth $9,817,158. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new position in shares of Cytokinetics in the fourth quarter worth $657,000. Alpine Global Management LLC purchased a new stake in shares of Cytokinetics in the fourth quarter worth about $381,000. Pacer Advisors Inc. boosted its position in shares of Cytokinetics by 76.5% in the fourth quarter. Pacer Advisors Inc. now owns 27,783 shares of the biopharmaceutical company’s stock valued at $1,765,000 after acquiring an additional 12,043 shares during the period. Invesco Ltd. boosted its position in shares of Cytokinetics by 30.3% in the fourth quarter. Invesco Ltd. now owns 204,878 shares of the biopharmaceutical company’s stock valued at $13,018,000 after acquiring an additional 47,629 shares during the period. Finally, Corient Private Wealth LLC grew its stake in Cytokinetics by 527.1% during the fourth quarter. Corient Private Wealth LLC now owns 30,184 shares of the biopharmaceutical company’s stock valued at $1,918,000 after acquiring an additional 25,371 shares in the last quarter.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.